Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer clinical trial (NCT02283372). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer clinical trial (NCT02283372). Contact the study team or your healthcare provider for specific answers.

Question 3

What kind of monitoring will I need during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer clinical trial (NCT02283372). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer clinical trial (NCT02283372). Contact the study team or your healthcare provider for specific answers.

Question 5

How often will I need to come in for treatment and tests?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer clinical trial (NCT02283372). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer clinical trial (NCT02283372). Contact the study team or your healthcare provider for specific answers.

What this study is about